Brief report: Clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice

Korean Multiple Myeloma Working Party

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Despite the recently reported efficacy of daratumumab monotherapy for patients with relapsed or refractory multiple myeloma, outcomes in real practice following daratumumab monotherapy have yet to be investigated. A multi-center retrospective study of 16 Korean patients receiving daratumumab monotherapy for relapsed or refractory multiple myeloma was conducted. The overall response rate was 56.3%. Three patients with creatinine clearance <30 ml/min even achieved an overall response. The median progression-free survival was 2.7 months with 28.9% (95% CI, 9.0-52.8) of 6-month progression-free survival. All infusion-related reactions, including ≥Grade 3 back pain (6.3%) and dyspnea (6.3%), were manageable. The most common hematologic and non-hematological adverse events were anemia (62.5%) and upper respiratory infection (43.8%). ≥Grade 3 bacterial infectious adverse events were identified, including upper and lower respiratory infection (12.5% and 18.8%) and death following sepsis (6.3%). We observed acceptable outcomes of daratumumab monotherapy on relapsed or refractory multiple myeloma patients including even a few subjects with high comorbidity, despite relatively frequent infectious adverse events.

Original languageEnglish
Pages (from-to)92-95
Number of pages4
JournalJapanese Journal of Clinical Oncology
Volume49
Issue number1
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Multiple Myeloma
Emergencies
Respiratory Tract Infections
Disease-Free Survival
Back Pain
Dyspnea
Comorbidity
Anemia
Creatinine
Sepsis
Retrospective Studies
daratumumab

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Brief report : Clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice. / Korean Multiple Myeloma Working Party.

In: Japanese Journal of Clinical Oncology, Vol. 49, No. 1, 01.01.2019, p. 92-95.

Research output: Contribution to journalArticle

@article{17af14d0ef3c403dab28821248f7197d,
title = "Brief report: Clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice",
abstract = "Despite the recently reported efficacy of daratumumab monotherapy for patients with relapsed or refractory multiple myeloma, outcomes in real practice following daratumumab monotherapy have yet to be investigated. A multi-center retrospective study of 16 Korean patients receiving daratumumab monotherapy for relapsed or refractory multiple myeloma was conducted. The overall response rate was 56.3{\%}. Three patients with creatinine clearance <30 ml/min even achieved an overall response. The median progression-free survival was 2.7 months with 28.9{\%} (95{\%} CI, 9.0-52.8) of 6-month progression-free survival. All infusion-related reactions, including ≥Grade 3 back pain (6.3{\%}) and dyspnea (6.3{\%}), were manageable. The most common hematologic and non-hematological adverse events were anemia (62.5{\%}) and upper respiratory infection (43.8{\%}). ≥Grade 3 bacterial infectious adverse events were identified, including upper and lower respiratory infection (12.5{\%} and 18.8{\%}) and death following sepsis (6.3{\%}). We observed acceptable outcomes of daratumumab monotherapy on relapsed or refractory multiple myeloma patients including even a few subjects with high comorbidity, despite relatively frequent infectious adverse events.",
author = "{Korean Multiple Myeloma Working Party} and Park, {Sung Soo} and Eom, {Hyeon Seok} and Kim, {Jin Seok} and Youngil Koh and Choi, {Chul Won} and Lee, {Je Jung} and Kihyun Kim and Cheolwon Suh and Lee, {Jae Hoon} and Min, {Chang Ki}",
year = "2019",
month = "1",
day = "1",
doi = "10.1093/jjco/hyy177",
language = "English",
volume = "49",
pages = "92--95",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Brief report

T2 - Clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice

AU - Korean Multiple Myeloma Working Party

AU - Park, Sung Soo

AU - Eom, Hyeon Seok

AU - Kim, Jin Seok

AU - Koh, Youngil

AU - Choi, Chul Won

AU - Lee, Je Jung

AU - Kim, Kihyun

AU - Suh, Cheolwon

AU - Lee, Jae Hoon

AU - Min, Chang Ki

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Despite the recently reported efficacy of daratumumab monotherapy for patients with relapsed or refractory multiple myeloma, outcomes in real practice following daratumumab monotherapy have yet to be investigated. A multi-center retrospective study of 16 Korean patients receiving daratumumab monotherapy for relapsed or refractory multiple myeloma was conducted. The overall response rate was 56.3%. Three patients with creatinine clearance <30 ml/min even achieved an overall response. The median progression-free survival was 2.7 months with 28.9% (95% CI, 9.0-52.8) of 6-month progression-free survival. All infusion-related reactions, including ≥Grade 3 back pain (6.3%) and dyspnea (6.3%), were manageable. The most common hematologic and non-hematological adverse events were anemia (62.5%) and upper respiratory infection (43.8%). ≥Grade 3 bacterial infectious adverse events were identified, including upper and lower respiratory infection (12.5% and 18.8%) and death following sepsis (6.3%). We observed acceptable outcomes of daratumumab monotherapy on relapsed or refractory multiple myeloma patients including even a few subjects with high comorbidity, despite relatively frequent infectious adverse events.

AB - Despite the recently reported efficacy of daratumumab monotherapy for patients with relapsed or refractory multiple myeloma, outcomes in real practice following daratumumab monotherapy have yet to be investigated. A multi-center retrospective study of 16 Korean patients receiving daratumumab monotherapy for relapsed or refractory multiple myeloma was conducted. The overall response rate was 56.3%. Three patients with creatinine clearance <30 ml/min even achieved an overall response. The median progression-free survival was 2.7 months with 28.9% (95% CI, 9.0-52.8) of 6-month progression-free survival. All infusion-related reactions, including ≥Grade 3 back pain (6.3%) and dyspnea (6.3%), were manageable. The most common hematologic and non-hematological adverse events were anemia (62.5%) and upper respiratory infection (43.8%). ≥Grade 3 bacterial infectious adverse events were identified, including upper and lower respiratory infection (12.5% and 18.8%) and death following sepsis (6.3%). We observed acceptable outcomes of daratumumab monotherapy on relapsed or refractory multiple myeloma patients including even a few subjects with high comorbidity, despite relatively frequent infectious adverse events.

UR - http://www.scopus.com/inward/record.url?scp=85059502898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059502898&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyy177

DO - 10.1093/jjco/hyy177

M3 - Article

C2 - 30476124

AN - SCOPUS:85059502898

VL - 49

SP - 92

EP - 95

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 1

ER -